Pembrolizumab Clinical Trials
473 recruitingDrug
Phase 2281Phase 1164Phase 393Early Phase 16Not Applicable5Phase 43
Showing 1–20 of 473 trials
Recruiting
Phase 2
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled159 locationsNCT07061964
Recruiting
Phase 1Phase 2
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled7 locationsNCT06047379
Recruiting
Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Stage III Thymoma AJCC v8Stage IIIA Thymoma AJCC v8Stage IIIB Thymoma AJCC v8+4 more
M.D. Anderson Cancer Center37 enrolled1 locationNCT03295227
Recruiting
Phase 2
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center144 enrolled1 locationNCT06004336
Recruiting
Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled319 locationsNCT06096844
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled366 locationsNCT06890598
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled401 locationsNCT05920356
Recruiting
Phase 2
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Jonsson Comprehensive Cancer Center21 enrolled1 locationNCT05775471
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled781 locationsNCT03486873
Recruiting
Phase 3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Advanced Melanoma
Replimune, Inc.400 enrolled81 locationsNCT06264180
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled177 locationsNCT06589804
Recruiting
Phase 2
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Muscle Invasive Bladder Cancer
Astellas Pharma Global Development, Inc.240 enrolled12 locationsNCT07475806
Recruiting
Phase 1Phase 2
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.92 enrolled17 locationsNCT07287917
Recruiting
Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled46 locationsNCT05365581
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled286 locationsNCT06357533
Recruiting
Phase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled257 locationsNCT06422806
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled356 locationsNCT05633654
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled134 locationsNCT06770582
Recruiting
Phase 2
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
Urothelial Carcinoma
University of Michigan Rogel Cancer Center32 enrolled2 locationsNCT06356155
Recruiting
Phase 3
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Ovarian Neoplasms
GlaxoSmithKline450 enrolled5 locationsNCT07286266